The leading group of pharmaceutical enterprises adjusts the R & D pipeline, focusing on this field

[pharmaceutical network industry trends] according to the data, the bio pharmaceutical market has achieved rapid growth from 2011 to 2018 It is predicted that China's biopharmaceuticals will continue to develop at a high speed from 2016 to 2020 By 2020, the market size will reach 33.3 billion yuan, with a compound growth rate of 18.1% There is a huge development space in the future In the face of this huge market, GSK, MSD, Roche and other multinational pharmaceutical companies have accelerated the adjustment of global R & D pipeline, focused on the core areas by selling and cutting off the research projects, and focused on the field of biological medicine For example, recently, in order to reduce the R & D pipeline and focus more on oncology and immunology, GSK agreed to sell rabipur / rabavert two vaccines for rabies, tick borne brain vaccine and encepur (TB E vaccine) to Bavaria Nordic company At the same time, cancer experts are hired from Merck, Novartis, AstraZeneca and other companies to cooperate with 23andMe and crispr-cas9 pioneers, with the goal of reshaping the choice of drug targets in the pharmaceutical industry It can be seen that GSK hopes to achieve a major breakthrough in the field of tumor and immune In order to focus more on innovation and R & D and seize growth opportunities, MSD also announced a large-scale layoff plan, which will cut about 500 jobs in several states of the United States from January 3, 2020 Layoffs will mainly affect some sales and headquarters business teams, but will increase U.S jobs in growth areas such as oncology, the source said In addition, Novartis sold its Suzhou plant as a whole in September in order to divest its non core business and adjust its business focus In addition, it also agreed to sell its subsidiary Sandoz's skin disease business and oral imitated solid preparation business in the United States to alabingo pharmaceutical company for us $1 billion It also announced the sale of a 36.5% stake in GlaxoSmithKline's consumer healthcare joint venture to GlaxoSmithKline for $13 billion and the split of Alcon's eye care business into an independent company From the frequent actions of multinational pharmaceutical companies, it can be seen that they have great confidence in the development of biopharmaceuticals and attach great importance to the research and development pipeline of biopharmaceuticals In the face of this situation, domestic pharmaceutical companies have begun to accelerate the layout in the field of biological medicine Earlier, the group announced that Jiaxi, a wholly-owned subsidiary of the company, would enter into an agreement with Yongshun technology to acquire all the issued shares of Yongshun technology at a price of RMB 253 million Yongshun group, established in 2012, is mainly engaged in the research and development of new monoclonal antibodies for targeting tumor antigens and multiple cancer immunotherapy It has obtained three new experimental drug approvals from the State Drug Administration on the following two research projects (jmt101 and jmt103), and has strong research and development capacity of biopharmaceutical drugs It can be seen from this that Shiyao Group intends to achieve curve overtaking through the bio pharmaceutical track Hengrui medicine has already announced that its biological similar drug product bevacizumab has been approved for clinical trials According to IMS database, the sales volume of bevacizumab injection in China in 2017 was about US $100 million At present, dozens of domestic enterprises have obtained the clinical trial approval documents of bevacizumab injection and its similar products, and no such products and its similar products have been approved for production The industry believes that Hengrui medicine has a positive layout and bevacizumab is expected to play an important role in the company's future cancer treatment combined drug system In addition, in April 2019, SHP chose to establish a R & D center in San Diego, the bio pharmaceutical valley of the United States The R & D center will be devoted to foreign cooperation and equity investment in bio pharmaceuticals, helping SHP borrow innovative talents and resources from the United States In addition, green leaf manufacturing has landed its R & D center in Boston in 2017, and plans to make the center undertake the global life science innovation strategy of green leaf layout, involving basic R & D in biomedicine, gene therapy and other fields Driven by the growing R & D investment, major development of biotechnology and favorable policies, it is expected that the market of original research biopharmaceuticals will continue to grow in the near future At the same time, the global market of bio similar drugs will continue to expand driven by factors such as the expiration of the protection of the original bio similar drugs, the increase of demand for drugs with similar efficacy and lower price, the development of good regulatory system and the improvement of research and development capacity of bio similar drug manufacturers In the future, the R & D pipeline with strong strength and rich products will determine the development trend of pharmaceutical enterprises.